Volume 17, Issue 10, Pages 1396-1408 (October 2016) Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open- label, international, randomised controlled trial  Prof Neyssa M Marina, MD, Prof Sigbjørn Smeland, MD, Prof Stefan S Bielack, MD, Prof Mark Bernstein, MD, Gordana Jovic, PhD, Mark D Krailo, PhD, Jane M Hook, MRCP, Prof Carola Arndt, MD, Henk van den Berg, MD, Bernadette Brennan, MD, Prof Bénédicte Brichard, MD, Ken L B Brown, MD, Trude Butterfass-Bahloul, MD, Gabriele Calaminus, MD, Heike E Daldrup-Link, MD, Mikael Eriksson, MD, Mark C Gebhardt, MD, Prof Hans Gelderblom, MD, Joachim Gerss, PhD, Robert Goldsby, MD, Allen Goorin, MD, Prof Richard Gorlick, MD, Prof Holcombe E Grier, MD, Juliet P Hale, MD, Kirsten Sundby Hall, MD, Prof Jendrik Hardes, MD, Douglas S Hawkins, MD, Prof Knut Helmke, MD, Prof Pancras C W Hogendoorn, MD, Michael S Isakoff, MD, Katherine A Janeway, MD, Prof Heribert Jürgens, MD, Leo Kager, MD, Prof Thomas Kühne, MD, Ching C Lau, MD, Prof Patrick J Leavey, MD, Prof Stephen L Lessnick, MD, Leo Mascarenhas, MD, Prof Paul A Meyers, MD, Hubert Mottl, MD, Prof Michaela Nathrath, MD, Prof Zsuzsanna Papai, MD, Prof R Lor Randall, MD, Peter Reichardt, MD, Marleen Renard, MD, Akmal Ahmed Safwat, PhD, Prof Cindy L Schwartz, MD, Prof Michael C G Stevens, MD, Sandra J Strauss, PhD, Lisa Teot, MD, Mathias Werner, MD, Matthew R Sydes, MSc, Prof Jeremy S Whelan, MD  The Lancet Oncology  Volume 17, Issue 10, Pages 1396-1408 (October 2016) DOI: 10.1016/S1470-2045(16)30214-5 Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

Figure 1 Trial profile *We later found out that one patient actually had a good histological response (allocated to MAP group at randomisation and analysed as in the MAP group). †One additional patient completed MAP (as he was not assessed for toxicity, he was excluded previously in this diagram). ‡One patient was lost to follow-up at randomisation. The Lancet Oncology 2016 17, 1396-1408DOI: (10.1016/S1470-2045(16)30214-5) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

Figure 2 Event-free survival (A) Kaplan-Meier curve of event-free survival. (B) Absolute difference in event-free survival by flexible parametric model difference. 95% CI is shown by shading. (C) Kaplan-Meier curve of event-free survival by metastases status at registration. The Lancet Oncology 2016 17, 1396-1408DOI: (10.1016/S1470-2045(16)30214-5) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

Figure 3 Kaplan-Meier curve of overall survival The Lancet Oncology 2016 17, 1396-1408DOI: (10.1016/S1470-2045(16)30214-5) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions